Members of Maryland Congressional Delegation Send Letter to Pfizer CEO

MedImmune Corporate Headquarters Photo | Jeffrey Sauers via MedImmune

MedImmune Corporate Headquarters
Photo | Jeffrey Sauers via MedImmune

Six members of the Maryland Congressional delegation have written to Pfizer CEO Ian Read concerning the company’s potential acquisition of AstraZeneca, which employs over 3,000 in Maryland. The letter was led by Congressman John K. Delaney (MD-6) whose district includes the Gaithersburg headquarters of AstraZeneca subsidiary MedImmune.

The letter was signed by Senator Barbara A. Mikulski, Senator Ben Cardin, Congressman C.A. Dutch Ruppersberger (MD-2), Congressman Chris Van Hollen (MD-8), Congressman John Sarbanes (MD-3) and Congressman John K. Delaney (MD-6).

The text of the letter is below:

Dear Mr. Read,

We are writing to express our concern about potential job losses in our state that could flow from Pfizer’s potential takeover of AstraZeneca. We understand you are likely to submit another offer before a May 26 deadline. As you review your options moving forward, we request you give serious consideration to the US jobs at stake in this possible acquisition. Particularly, AstraZeneca currently employs over 3,000 people in Maryland.

It has been widely reported that if a deal moves forward, Pfizer has committed to keeping at least 20 percent of the combined company’s research and development workforce in the UK for at least five years, as well as retaining substantial manufacturing facilities at AstraZeneca’s site south of Manchester. Given the distribution of AstraZeneca’s current workforce, we worry that jobs in the United States would be eliminated in the takeover.

As you evaluate your next steps, we ask you to extend similar assurances to those you gave in the UK to the research and development workforce in Maryland. AstraZeneca and its MedImmune subsidiary have strong presences in the state, and their workforces are highly skilled and extremely effective. In addition, the MedImmune research facility in Maryland has an international reputation for world-class expertise and is located in the heart of our nation’s biotech corridor near the National Institutes of Health. If a deal moves forward, Pfizer would benefit greatly from maintaining their Maryland facilities and workforce.

Thank you for your attention in the matter, and we look forward to your response.

Sincerely,

Senator Barbara A. Mikulski
Senator Benjamin L. Cardin
C.A. Dutch Ruppersberger Member of Congress
Chris Van Hollen Member of Congress
John Sarbanes Member of Congress
John K. Delaney Member of Congress

 

Related Posts: 

Five Things to Know Today, Oct. 15, in Montgomery County

Five Things List-03 for slider

Here are your five things to know today, Oct. 15, in Montgomery County: 1. Crews are finishing road repairs at the scene of Tuesday’s water main break at Rockville Pike and Cedar Lane. According to WSSC, all southbound lanes should be open by 8 a.m. today. All northbound lanes are already open. 2. The Maryland […]

Read more

Gaithersburg Public Hearing Set for Proposed MedImmune Parking Garage

medimmune2

The Gaithesburg City Council and Planning Commission will hold a joint public hearing at 7:30 p.m. on July 20th to discuss a schematic development plan (SDP) application for construction of a structured parking garage on the MedImmune/Astrazeneca campus. The proposed parking garage would include 1,386 spaces to serve future development on the company’s Gaithersburg campus. […]

Read more

MedImmune Alerts Community of Plans to Build Childcare Center

medimmune2

UPDATED MedImmune and AstraZeneca officials are planning to build a child care center adjacent to the company’s corporate campus at One MedImmune Way in Gaithersburg. In an email sent on Feb. 11, the biotech company alerted Quince Orchard Park community residents that a Schematic Development Plan (SDP) application for construction of the child care center […]

Read more

Members of Maryland Congressional Delegation Send Letter to Pfizer CEO

MedImmune Corporate Headquarters
Photo | Jeffrey Sauers via MedImmune

Six members of the Maryland Congressional delegation have written to Pfizer CEO Ian Read concerning the company’s potential acquisition of AstraZeneca, which employs over 3,000 in Maryland. The letter was led by Congressman John K. Delaney (MD-6) whose district includes the Gaithersburg headquarters of AstraZeneca subsidiary MedImmune. The letter was signed by Senator Barbara A. […]

Read more

Governors Send Joint Letter of Concern about Potential Acquisition of AstraZeneca

MedImmune Corporate Headquarters
Photo | Jeffrey Sauers via MedImmune

Maryland Governor Martin O’Malley and Deleware Governor Jack Markell sent a letter today to Ian Read, chairman and Chief Executive Officer of Pfizer, Inc., expressing deep concerns about the potential acquisition of AstraZeneca PLC. The letter highlights the potentially significant impact on good, family-sustaining jobs in both Maryland and Delaware, and expresses concern about the […]

Read more

MedImmune Names Dr. Liu Head of Research

MedImmune Corporate Headquarters
Photo | Jeffrey Sauers via MedImmune

Gaithersburg based MedImmune, the global biologics research and development arm of AstraZeneca, announced Nov. 14 that Yong-Jun Liu, M.D., Ph.D. has been named the company’s new head of research, effective Jan. 6, 2014. Dr. Liu currently serves as vice president and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute […]

Read more

AstraZeneca Advances MedImmune's Benralizumab to Phase III

MedImmune Corporate Headquarters
Photo | Jeffrey Sauers via MedImmune

AstraZeneca announced (Oct. 30) the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company’s global biologics research and development arm. The goal of CALIMA, the first study in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients […]

Read more

MedImmune Acquires Amplimmune

AstraZeneca PLC

MedImmune, completed its acquisition of Amplimmune, a privately-held, Gaithersburg based biologics company focused on developing novel therapeutics in cancer immunology. MedImmune acquired 100% of Amplimmune’s shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching established development milestones. Founded in 2007 and headquartered in Gaithersburg, Amplimmune […]

Read more

MedImmune to Acquire Amplimmune (Photo)

photo test tube

AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology. The buyout is designed to strengthen MedImmune’s cancer-related research, and includes an initial payment of $225 million, with the possibility of another […]

Read more

AstraZeneca Announces Strategic Gaithersburg R & D Center

cicmedimmune2

UPDATED “Certainly a big win for the city,” said Gaitherburg Economic Development Director Tom Lonergan at the March 18 Gaithersburg City Council meeting. Lonergan said the AstraZeneca plans to add 300 more jobs to the MedImmune campus over the next few years. ——————————————————————– AstraZeneca announced on March 18 that Gaithersburg will be one of three […]

Read more
Like this post? Sign up for our Daily Update here.

Comments

| No comments yet.



Engage us on Facebook

Follow us on Twitter